oral glp-1 drugs BREAKING: The FDA has approved the first pill for obesity, marking a major milestone in the weight-loss drug market and a potential inflection point for treatment access. The daily pill, BREAKING: The FDA has approved
Description
A recent study, published in the Journal of Pharmacy and Pharmacology Research, sugges
Background Establishing whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is crucial for public safety
After their success in the obesity field, GLP-1 agonists are gaining interest in addiction treatment
Insurers raised cost-sharing sharply for GLP-1s in recent years and also increased use of prior authorization.
Very few include older adults at high risk
If you are taking medications or have a medical condition, speak with your provider before use
